ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Adiponectin inhibits VEGF-A in prostate cancer cells.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Unravelling the Adiponectin Hallmark and Exploring the Therapeutic Potential of Its Receptor Agonists in Cancer Metabolic Reprogramming.Biomolecules · 2025Review
- Therapeutic Potential of Anti-Diabetes Drugs and Anti-Dyslipidemia Drugs to Mitigate Head and Neck Cancer Risk in Metabolic Syndrome.CNS neuroscience & therapeutics · 2025Review
- Combination of Blood Adiponectin and Leptin Levels Is a Predictor of Biochemical Recurrence in Prostate Cancer Invading the Surrounding Adipose Tissue.International journal of molecular sciences · 2024Article
- Article
- The mysterious association between adiponectin and endometriosis.Frontiers in pharmacology · 2024Review
- Role of Leptin and Adiponectin in Carcinogenesis.Cancers · 2023Review
- Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.Discover oncology · 2023Review
- Multidisciplinary Progress in Obesity Research.Genes · 2022Review
- Interplay between Prostate Cancer and Adipose Microenvironment: A Complex and Flexible Scenario.International journal of molecular sciences · 2022Review
- Review
- Adiponectin: A player in the pathogenesis of hormone-dependent cancers.Frontiers in endocrinology · 2022Review
- Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour.International journal of molecular sciences · 2021Review
- Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression.International journal of molecular sciences · 2021Review
- The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.International journal of molecular sciences · 2019Review
- Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers.Cancers · 2019Review
- Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk.International journal of molecular sciences · 2019Review
- Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease.International journal of molecular sciences · 2019Review
- Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats.Biochemistry and biophysics reports · 2018Article
- Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A.Cell proliferation · 2018Article
- Obesity and Cancer: Existing and New Hypotheses for a Causal Connection.EBioMedicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A role of adiponectin in tumorigenesis has recently been appreciated. Although plasma adiponectin levels in subjects with prostate cancer have been found to be significantly lower than in subjects with benign prostatic hyperplasia or in normal healthy controls, the underlying molecular mechanisms remain unknown. Here, we not only detected significant decreases in plasma adiponectin levels in prostate cancer patients, but also showed significant decreases in adiponectin receptor I (AdipoR1) levels in the resected prostate cancer specimen. Prostate cancer cell lines examined in the current study had all lower levels of adiponectin and AdipoR1, compared to normal healthy prostate tissue. Moreover, overexpression of adiponectin in prostate cancer cells decreased production of vascular endothelial growth factor A (VEGF-A), while adiponectin depletion increased VEGF-A. Furthermore, adiponectin seemed to activate AMPK/TSC2 to inhibit mTor-mediated activation of VEGF-A. Taken together, our data suggest that adiponectin may play an essential role in suppressing growth of prostate cancer cells through inhibition of VEGF-A-mediated cancer neovascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.